4.15
+0.11(+2.72%)
Currency In USD
| Previous Close | 4.04 |
| Open | 3.99 |
| Day High | 4.27 |
| Day Low | 3.97 |
| 52-Week High | 5.18 |
| 52-Week Low | 0.95 |
| Volume | 5.68M |
| Average Volume | 8.21M |
| Market Cap | 591.13M |
| PE | -14.82 |
| EPS | -0.28 |
| Moving Average 50 Days | 3.36 |
| Moving Average 200 Days | 2.15 |
| Change | 0.11 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.16 as of February 21, 2026 at a share price of $4.15. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $475.37 as of February 21, 2026 at a share price of $4.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
GlobeNewswire Inc.
Jan 14, 2026 1:30 PM GMT
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Dec 29, 2025 1:35 PM GMT
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the final analysis is event-driven, and SELLAS will annou
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
GlobeNewswire Inc.
Dec 07, 2025 11:00 PM GMT
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-bas